awmsg logo



everolimus (Votubia®)


Reference No. 873

Publication date:
08/03/2012


Appraisal information

everolimus (Votubia®) 2.5 mg tablet
everolimus (Votubia®) 5 mg tablet
everolimus (Votubia®) 10 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/03/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, everolimus (Votubia®) cannot be endorsed for use within NHS Wales for the treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex who require therapeutic intervention but are not amenable to surgery.
Statement of Advice (SOA)
Download